Tags

Type your tag names separated by a space and hit enter

Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
J Pediatr Endocrinol Metab 2013; 26(11-12):1105-10JP

Abstract

OBJECTIVE

To assess the user-friendliness of the Norditropin FlexPro (Novo Nordisk A/S, Bagsvaerd, Denmark), a newly developed growth hormone (GH) injection pen.

METHODS

This study consisted of a single-center, single-arm, open-label, questionnaire based survey of patients undergoing GH treatment for diverse indications who were scheduled to switch from the formerly used device Norditropin NordiFlex (Novo Nordisk A/S) to the FlexPro and evaluate each device's usability.

RESULTS

A total of 82 patients participated in the study. Compared to the NordiFlex, the FlexPro was regarded as easier to grip, easier to hold during injection, and more stable during injection. The degree of pain at insertion perceived by the patient and the patient's fear of injection were significantly decreased when using the FlexPro, and 81% of the respondents selected the FlexPro as the more preferable device.

CONCLUSIONS

The FlexPro was more user-friendly than the NordiFlex. Perception of pain at insertion and fear of injection were lessened by using the FlexPro.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23843576

Citation

Adachi, Masanori. "Assessment of User-friendliness of the Norditropin FlexPro for Pediatric Patients Treated With Recombinant Human Growth Hormone: Results of an Open-label User Survey." Journal of Pediatric Endocrinology & Metabolism : JPEM, vol. 26, no. 11-12, 2013, pp. 1105-10.
Adachi M. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey. J Pediatr Endocrinol Metab. 2013;26(11-12):1105-10.
Adachi, M. (2013). Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey. Journal of Pediatric Endocrinology & Metabolism : JPEM, 26(11-12), pp. 1105-10. doi:10.1515/jpem-2013-0071.
Adachi M. Assessment of User-friendliness of the Norditropin FlexPro for Pediatric Patients Treated With Recombinant Human Growth Hormone: Results of an Open-label User Survey. J Pediatr Endocrinol Metab. 2013;26(11-12):1105-10. PubMed PMID: 23843576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey. A1 - Adachi,Masanori, PY - 2013/02/19/received PY - 2013/06/12/accepted PY - 2013/7/12/entrez PY - 2013/7/12/pubmed PY - 2014/7/17/medline SP - 1105 EP - 10 JF - Journal of pediatric endocrinology & metabolism : JPEM JO - J. Pediatr. Endocrinol. Metab. VL - 26 IS - 11-12 N2 - OBJECTIVE: To assess the user-friendliness of the Norditropin FlexPro (Novo Nordisk A/S, Bagsvaerd, Denmark), a newly developed growth hormone (GH) injection pen. METHODS: This study consisted of a single-center, single-arm, open-label, questionnaire based survey of patients undergoing GH treatment for diverse indications who were scheduled to switch from the formerly used device Norditropin NordiFlex (Novo Nordisk A/S) to the FlexPro and evaluate each device's usability. RESULTS: A total of 82 patients participated in the study. Compared to the NordiFlex, the FlexPro was regarded as easier to grip, easier to hold during injection, and more stable during injection. The degree of pain at insertion perceived by the patient and the patient's fear of injection were significantly decreased when using the FlexPro, and 81% of the respondents selected the FlexPro as the more preferable device. CONCLUSIONS: The FlexPro was more user-friendly than the NordiFlex. Perception of pain at insertion and fear of injection were lessened by using the FlexPro. SN - 2191-0251 UR - https://www.unboundmedicine.com/medline/citation/23843576/Assessment_of_user_friendliness_of_the_Norditropin_FlexPro_for_pediatric_patients_treated_with_recombinant_human_growth_hormone:_results_of_an_open_label_user_survey_ L2 - https://www.degruyter.com/doi/10.1515/jpem-2013-0071 DB - PRIME DP - Unbound Medicine ER -